Investigating stem cells from patients with neurodegenerative diseases
Study of Neurological Pathological Mechanisms of and Neurodegenerative Diseases in Neurons and Glia Derived From Induced Stem Cells (iPS) in Patients and Healthy Family Controls.
This study is trying to create special stem cells from people with neurodegenerative diseases and their healthy family members to better understand these conditions and find new treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Sex | All |
| Sponsor | Neuromed IRCCS Academic / other |
| Locations | 1 site (Pozzilli, Isernia) |
| Trial ID | NCT03682458 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on generating induced pluripotent stem cells (iPS) from patients diagnosed with neurodegenerative diseases and healthy family controls. By reprogramming somatic cells, the study aims to create in vitro models that accurately reflect the molecular and biochemical characteristics of these diseases. The research leverages the expertise of the proposing group in differentiating iPS cells into neurons and glial cells, which could enhance our understanding of neurodegenerative conditions and aid in developing effective therapies.
Who should consider this trial
Good fit: Ideal candidates include individuals with a clinical diagnosis of a neurodegenerative disease and identifiable gene variants related to their condition.
Not a fit: Patients without a clinical diagnosis of neurodegenerative diseases or those lacking identifiable gene variants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved models for understanding neurodegenerative diseases and potentially pave the way for new therapeutic strategies.
How similar studies have performed: Other studies utilizing iPS technology have shown promise in modeling neurodegenerative diseases, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of neurodegenerative disease * identification of gene variant of interest compatible with the clinical phenotype. Exclusion Criteria: * no identification of gene variant of interest compatible with the clinical phenotype.
Where this trial is running
Pozzilli, Isernia
- Stefano Gambardella — Pozzilli, Isernia, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.